IL23A and atopic eczema: IL23A, IL4, IL13, and TNFR1 are targets of medically efficacious drugs in widespread use in psoriasis and atopic dermatitis, consistent with the observed enhanced likelihood of success for polygenic disease therapeutics directed at GWAS-linked targets.